AMG National Trust Bank Raises Holdings in Stryker Corporation $SYK

AMG National Trust Bank grew its position in Stryker Corporation (NYSE:SYK) by 0.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,695 shares of the medical technology company’s stock after buying an additional 122 shares during the quarter. AMG National Trust Bank’s holdings in Stryker were worth $6,209,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Mar Vista Investment Partners LLC lifted its stake in shares of Stryker by 10.2% during the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock worth $33,572,000 after purchasing an additional 8,353 shares during the last quarter. United Services Automobile Association purchased a new stake in shares of Stryker during the 1st quarter worth $2,857,000. AXS Investments LLC lifted its stake in shares of Stryker by 13.7% during the 1st quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock worth $3,286,000 after purchasing an additional 1,062 shares during the last quarter. Park Edge Advisors LLC purchased a new stake in shares of Stryker during the 2nd quarter worth $679,000. Finally, Hendley & Co. Inc. lifted its stake in shares of Stryker by 60.3% during the 2nd quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company’s stock worth $5,546,000 after purchasing an additional 5,274 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SYK. Truist Financial reduced their target price on Stryker from $415.00 to $407.00 and set a “hold” rating on the stock in a research report on Wednesday, October 15th. Redburn Partners set a $420.00 target price on Stryker in a research report on Thursday, September 18th. Evercore ISI reduced their target price on Stryker from $418.00 to $410.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 7th. UBS Group set a $408.00 target price on Stryker in a research report on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a research report on Wednesday, October 8th. Thirteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $434.32.

Insider Transactions at Stryker

In other news, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 5.90% of the stock is currently owned by corporate insiders.

Stryker Stock Down 0.1%

Shares of SYK stock opened at $369.31 on Friday. The stock’s 50-day simple moving average is $378.83 and its 200-day simple moving average is $380.54. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market capitalization of $141.19 billion, a PE ratio of 48.92, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s dividend payout ratio is currently 44.50%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.